3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Neoplasms
2
Thrombocythemia, Essential
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Pinealoma
1
Pancreatic Cancer Metastatic
1
Osteosarcoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Myeloproliferative Disorders
1
Medulloblastoma
1
Leukemia, Myelomonocytic, Chronic
1
Histiocytosis, Langerhans-Cell
1
Ependymoma
1
Carcinoma
1
Brain Neoplasms
1
Interventions
X-Rays
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Biopsy
4
ulixertinib
2
tipifarnib
2
selpercatinib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Cyclophosphamide
2
tazemetostat
1
palbociclib
1
olaparib
1
fludarabine phosphate
1
fludarabine
1
etoposide phosphate
1
Vemurafenib
1
Thiotepa
1
Tacrolimus
1
Sirolimus
1
Pharmacogenomic Variants
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Melphalan
1
Lenalidomide
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Histiocytosis, Langerhans-Cell
×
Celecoxib
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled